Form 4: Relay Therapeutics Director Douglas Ingram Receives Significant Stock Option Grant

Relay Therapeutics, Inc. Director Douglas S. Ingram was granted 136,681 stock options with an exercise price of $3.36, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Summary

• Douglas S. Ingram, a Director of Relay Therapeutics, Inc. (RLAY), was granted 136,681 stock options.
• The options have an exercise price of $3.36 per share.
• The grant date for these options is June 6, 2025.
• The options vest in full on the earlier of June 6, 2026 (the first anniversary of the grant date) or the date of the next annual meeting of stockholders following the grant date.
• The expiration date for these options is June 5, 2035.
• Following this transaction, Mr. Ingram directly beneficially owns 136,681 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns their interests with shareholders and incentivizes long-term performance. It's a routine compensation event rather than a major strategic announcement, hence a moderately positive score.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The options have a 10-year expiration period, providing a substantial window for potential value realization if the company's stock price appreciates.

Negatives

• The value of the options is entirely dependent on the future market price of Relay Therapeutics' common stock exceeding the exercise price of $3.36.

Risks

• The value of the stock options is subject to the volatility of Relay Therapeutics' common stock price, and there is no guarantee that the stock price will rise above the exercise price of $3.36.
• If the company's stock price does not perform well, the options may expire worthless, providing no financial benefit to the holder.

Future Outlook

The grant of stock options to a director indicates a long-term incentive structure, aligning management's future financial interests with the company's stock performance and potential growth.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to attract and retain talent while incentivizing long-term value creation. This practice is standard across many publicly traded companies, particularly in growth-oriented sectors like biotech, to align the interests of leadership with those of shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice in the biotechnology industry, used to incentivize long-term performance and align interests with shareholders.
• The vesting schedule (one year or next annual meeting) is typical for director equity grants, designed to ensure continued engagement and commitment.
• This Form 4 focuses solely on an individual's transaction and does not provide specific details for direct comparison to other companies' projects or results.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the director's financial interests with the company's stock performance.
• Employees: No direct impact mentioned in this filing.
• Customers: No direct impact mentioned in this filing.
• Suppliers: No direct impact mentioned in this filing.
• Creditors: No direct impact mentioned in this filing.

Next Steps

• Monitoring the vesting of the options on the earlier of June 6, 2026, or the date of the next annual meeting of stockholders.
• Observing any future exercises or sales of these options by Mr. Ingram, which would be reported in subsequent Form 4 filings.

Key Dates

Keywords

Relay Therapeutics, RLAY, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership, SEC Filing